COMPANIES COVERED
CelgeneDownload FREE Report Sample
Download Free sampleMyelodysplastic syndrome is caused by mutation of one or more genes that control development of blood cells. It is one of the most common malignant hematological diseases that affects five out of every 100,000 people in U.S. annually. An estimated 60,000 people in U.S. live with MDS, and approximately 10,000-15,000 new cases are reported each year. Patients may present with clinical manifestations such as thrombocytopenia, neutropenia, and anemia. Exposure to chemicals (such as pesticides, tobacco, and benzene) and heavy metals (such as mercury and lead) may trigger disease onset.
Myelodysplastic Syndrome Drugs Market contains market size and forecasts of Myelodysplastic Syndrome (MDS) Drugs in Global, including the following market information:
Global Myelodysplastic Syndrome (MDS) Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Myelodysplastic Syndrome (MDS) Drugs market was valued at 1496.4 million in 2021 and is projected to reach US$ 2170.3 million by 2028, at a CAGR of 5.5% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Hypomethylating Agents Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Myelodysplastic Syndrome (MDS) Drugs include Celgene, Amgen, Otsuka and Takeda, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Myelodysplastic Syndrome (MDS) Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Myelodysplastic Syndrome (MDS) Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Myelodysplastic Syndrome (MDS) Drugs Market Segment Percentages, by Type, 2021 (%)
Hypomethylating Agents
Immunomodulatory Drugs
Anti-anemics
Global Myelodysplastic Syndrome (MDS) Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Myelodysplastic Syndrome (MDS) Drugs Market Segment Percentages, by Application, 2021 (%)
Original
Generics
Global Myelodysplastic Syndrome (MDS) Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Myelodysplastic Syndrome (MDS) Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Myelodysplastic Syndrome (MDS) Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Myelodysplastic Syndrome (MDS) Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Celgene
Amgen
Otsuka
Takeda
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
